JP6450840B2 - 5−クロロ−n−({(5s)−2−オキソ−3−[4−(5,6−ジヒドロ−4h−[1,2,4]トリアジン−1−イル)フェニル]−1,3−オキサゾリジン−5−イル}メチル)チオフェン−2−カルボキシアミド メタンスルホネートの新規結晶形態および前記結晶形態を含む医薬組成物 - Google Patents
5−クロロ−n−({(5s)−2−オキソ−3−[4−(5,6−ジヒドロ−4h−[1,2,4]トリアジン−1−イル)フェニル]−1,3−オキサゾリジン−5−イル}メチル)チオフェン−2−カルボキシアミド メタンスルホネートの新規結晶形態および前記結晶形態を含む医薬組成物 Download PDFInfo
- Publication number
- JP6450840B2 JP6450840B2 JP2017523744A JP2017523744A JP6450840B2 JP 6450840 B2 JP6450840 B2 JP 6450840B2 JP 2017523744 A JP2017523744 A JP 2017523744A JP 2017523744 A JP2017523744 A JP 2017523744A JP 6450840 B2 JP6450840 B2 JP 6450840B2
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- pharmaceutical composition
- thiophene
- dihydro
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 16
- JUJNQUIRRLHBSX-UHFFFAOYSA-N CS(=O)(=O)O.S1C=CC=C1C(=O)N Chemical compound CS(=O)(=O)O.S1C=CC=C1C(=O)N JUJNQUIRRLHBSX-UHFFFAOYSA-N 0.000 title 1
- 239000013078 crystal Substances 0.000 claims description 59
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 16
- BJIOUIHGASIGMO-UHFFFAOYSA-N C1=CSC(=C1)C(=O)NCS(=O)(=O)O Chemical compound C1=CSC(=C1)C(=O)NCS(=O)(=O)O BJIOUIHGASIGMO-UHFFFAOYSA-N 0.000 claims description 14
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 238000001228 spectrum Methods 0.000 claims description 10
- YSNDMQDQQLSJMR-UQKRIMTDSA-N 5-chloro-n-[[(5s)-3-[4-(5,6-dihydro-2h-1,2,4-triazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2NC=NCC2)C1 YSNDMQDQQLSJMR-UQKRIMTDSA-N 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
- 208000005189 Embolism Diseases 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 208000001435 Thromboembolism Diseases 0.000 claims description 5
- 208000007536 Thrombosis Diseases 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 238000002399 angioplasty Methods 0.000 claims description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 230000000306 recurrent effect Effects 0.000 claims description 5
- 230000036262 stenosis Effects 0.000 claims description 5
- 208000037804 stenosis Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 20
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 16
- 239000002775 capsule Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000004090 dissolution Methods 0.000 description 10
- 238000002411 thermogravimetry Methods 0.000 description 10
- -1 5,6-dihydro-4H- [1,2,4] triazin-1-yl Chemical group 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 6
- 238000007922 dissolution test Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010022562 Intermittent claudication Diseases 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 208000021156 intermittent vascular claudication Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000012296 anti-solvent Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 244000171897 Acacia nilotica subsp nilotica Species 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OYEHFRMFJLFNSD-UHFFFAOYSA-N 1,2,5,6-tetrahydro-1,2,4-triazine Chemical compound C1CN=CNN1 OYEHFRMFJLFNSD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920003110 Primojel Polymers 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000017570 negative regulation of blood coagulation Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
本発明は、5-クロロ-N-({(5S)-2−オキソ−3-[4-(5,6-ジヒドロ-4H-[1,2,4]トリアジン-1−イル)フェニル]-1,3-オキサゾリジン-5-イル}メチル)チオフェン-2-カルボキシアミドメタンスルホネートの新規結晶形態およびそれを含む医薬組成物に関する。
本発明の目的は、均一かつ安定である5-クロロ-N-({(5S)-2−オキソ−3-[4-(5,6-ジヒドロ-4H-[1,2,4]トリアジン-1−イル)フェニル]-1,3-オキサゾリジン-5-イル}メチル)チオフェン-2-カルボキシアミドメタンスルホネートの新規結晶形態を提供することである。
本発明の上記および別の目的および特徴は、添付の図面と併せて、本発明の以下の説明から理解されるであろう。添付の図面は、各々以下を示す:
以下に本発明をより具体的に説明する。
本発明の5-クロロ-N-({(5S)-2−オキソ−3-[4-(5,6-ジヒドロ-4H-[1,2,4]トリアジン-1−イル)フェニル]-1,3-オキサゾリジン-5-イル}メチル)チオフェン-2-カルボキシアミドメタンスルホネート(以後「GCC-4401C」として示す)の新規結晶形態は、高温かつ高湿度環境において卓越した溶解性および安定性を有する。
以下に、本発明は、実施例により詳細に説明される。以下の実施例は、本発明の範囲を制限することなく本発明をさらに説明することが意図される。
1) X-線粉末回折(PXRD)スペクトルを、Cu-Kα線を使用するX線回折分光計(Bruker Corporation, Germany)により得た。PXRDスペクトルの測定に使用した機器および条件は、以下の表1に挙げられる。
3) TGAを、不活性窒素雰囲気下において、約30 mL/分にてShimadzu DTG-60を用いて実施した。温度を、10℃/分のランプスピードにて室温〜220℃に設定して、結果を、30℃〜105℃の範囲で積分した。
n-ブタノールを、室温で(30±5℃)、自動ポリブロック反応機器(POLYBLOCK 8-station (パラレル反応装置) Maker:HEL)に入れた。WO2011/005029の頁28〜35に記述された方法に従って製造された5-クロロ-N-({(5S)-2−オキソ−3-[4-(5,6-ジヒドロ-4H-[1,2,4]トリアジン-1−イル)フェニル]-1,3-オキサゾリジン-5-イル}メチル)チオフェン-2-カルボキシアミドメタンスルホネート(純度:99.7%)(15 g)を、8倍体積のメタノールに溶解した。得られる溶液を、ゆっくりと反応容器に添加した。n-ブタノールを、20倍体積の量にて使用した。
DSC ピーク:179.33℃
TGAによる重量減少:0.09% (w/w)
IR (KBr, cm-1): 3301, 3453, 3066, 2939, 2357, 2124, 2018, 1962, 1742, 1670, 1644, 1552, 1509, 1486, 1429, 1411, 1361, 1344, 1323, 1301, 1287, 1217, 1196, 1160, 1146, 1105, 1085, 1032, 991, 930, 882, 839, 821, 803, 776, 751, 729, 707, 683, 667.
13C NMR: 160.81, 154.16, 148.00, 143.43, 138.47, 134.06, 133.25, 128.45, 128.18, 119.35, 118.08, 71.32, 47.53, 45.94, 42.17, 40.13, 35.71.
メタノールを、室温(30±5℃)で、自動ポリブロック反応機器(POLYBLOCK 8-station (parallel reactor) Maker:HEL)に入れた。WO2011/005029の頁28〜35に記述された方法に従って製造された5-クロロ-N-({(5S)-2−オキソ−3-[4-(5,6-ジヒドロ-4H-[1,2,4]トリアジン-1−イル)フェニル]-1,3-オキサゾリジン-5-イル}メチル)チオフェン-2-カルボキシアミドメタンスルホネート(純度:99.7%)(20 g)を、反応容器に加えた。反応物質を、45±2℃に加熱して、透明な溶液を得た。
DSC ピーク:186℃
TGAによる重量減少:0.00% (w/w)
IR (KBr, cm-1): 3315, 3236, 3050, 2963, 2439, 2144, 2167, 2135, 2055, 2015, 1892, 1708, 1656, 1572, 1550, 1514, 1479, 1438, 1419, 1429, 1322, 1303, 1273, 1236, 1226, 1202, 1169, 1150, 1082, 1058, 1038, 1018, 996, 943, 882, 821, 807, 777, 757, 723, 685, 671, 655.
13C NMR: 160.81, 154.16, 148.00, 143.43, 138.47, 134.06, 133.25, 128.45, 128.18, 119.35, 118.08, 71.32, 47.53, 45.94, 42.17, 40.13, 35.71.
実施例1および2から得られた新規結晶形態の安定性を、以下の方法に従って測定した。
1) 溶媒スラリー系中の安定性の測定
1つの結晶形態が、攪拌した溶媒中で別の結晶形態へと相互変換されるかどうかを決定するために、スラリー試験を、室温で種々の溶媒中で行なった。
高温での結晶形態の相互変換を決定するために、結晶形1および5の各々を、非真空状態において80±5℃で乾燥させて、次いで30±5℃の温度に冷却した。DSC分析を、得られた試料について行ない、最終の結晶形態を同定した。表5は、その結果を示す。
表5に示したとおり、本発明の結晶形1および5は、高温で安定であることが確認された。
多重ミル、手作業でのグラインドおよび加湿試験を、本発明の結晶形態について行い、物理的刺激の下でそれらの安定性を確認した。多重ミル試験のために、結晶形1および5の各々を、プロトタイプの多重ミル機器(Sreenex Machines Pvt. Ltd.)を用いて3,000 rpmで粉砕した。手作業でのグラインドのために、各結晶形態を、乳棒と乳鉢を用いて徐々に粉砕した。加湿試験において、結晶形1および5を、30℃および90% RHで24時間貯蔵した。
本発明の各結晶形1および5の溶解度を、メタノール溶媒中に溶解した後に測定した。結果として、結晶形1の溶解度は、70 mg/mLであって、結晶形5の溶解度は30 mg/mLであり、このことは、結晶形5が結晶形1よりもより安定であることを示している。
1) カプセル剤の製造
本発明の結晶形1を含有するカプセル剤を、従来のカプセル化方法に従って製造した。最初に、20 mgの本発明の結晶形1および279.1 mgの乳糖を、V-ミキサーに加えて、これは、医薬品を製造するための混合法にて一般的に使用され、次いで20 rpm, 20分間混合した。0.9 mg のステアリン酸マグネシウムを、そこに加えて、混合物を、20 rpm, 5分間でさらに混合した。混合物を、硬ゼラチンカプセル剤中に充填して、結晶形1のカプセル剤を製造した。
本発明の結晶形1または5を含有する錠剤を、従来の錠剤化方法に従って製造した。
特に、20mgの結晶形1、175.5 mgの乳糖、7 mgのPrimojel、5 mgのヒドロキシプロピルメチルセルロース(HPMC)および1.5 mgのAerosil 200を、V-ミキサーに加えて、これを、医薬品を製造するための混合法にて一般的に使用して、20 rpmで20分間混合した。1 mg のステアリン酸マグネシウムを、それに加えて、この混合物を、さらに20 rpmで5分間混合した。混合物を、錠剤プレス器を用いて、錠剤へと圧縮した。結晶形1を含有するフィルム被覆された錠剤を、得られた錠剤を約10 mgのOpadryで被覆することにより製造した。
溶出試験を、上記で製造したカプセル剤および錠剤について実施して、その溶出率(%)を測定した。
溶出試験を、U.S.P.装置2のパドル方法に従って、50 rpmのパドルスピードで行なった。は、あった。酢酸緩衝液(pH 4.0)を、溶出用液として使用して、カプセル剤または錠剤を、溶出溶液(900 mL)が37±0.5℃となった時点で加えた。所定の時点(5分、10分、15分および30分)で、各試料1 mLを、溶出溶液から採取して、濾過した。溶出率を、HPLCを用いて測定した。この試験を、一回実施した(N=6)。溶出率の平均および標準偏差(S.D.)を、以下の表7および図7に示した。
大量生産における結晶形に拠る溶出パターンの類似性を確認するために、本発明の結晶形1および5を含有する錠剤を大量生産した(スケールアップ)。このようして得られた錠剤について、上記した同じ方法に従って溶出試験を行なった。表8および図8は、その結果を示している。
Claims (5)
- Cu-Kα線を使用するX線粉末回折スペクトルが、12.022、15.721、15.971、18.125、18.928、19.979、20.311、20.726、21.66、22.805、23.18、23.985、25.857、27.25、27.829、28、28.189および29.753である回折角度2θのピークを特徴とし、かつ30mg/mlのメタノール溶解度を示す、無水結晶の5-クロロ-N-({(5S)-2−オキソ−3-[4-(5,6-ジヒドロ-4H-[1,2,4]トリアジン-1−イル)フェニル]-1,3-オキサゾリジン-5-イル}メチル)チオフェン-2-カルボキシアミドメタンスルホネート(GCC-4401C)。
- 示差走査熱量測定分析において、186±2℃でピークを示す、請求項1に記載の無水結晶GCC-4401C。
- 請求項1または2に記載の無水結晶の5-クロロ-N-({(5S)-2−オキソ−3-[4-(5,6-ジヒドロ-4H-[1,2,4]トリアジン-1−イル)フェニル]-1,3-オキサゾリジン-5-イル}メチル)チオフェン-2-カルボキシアミドメタンスルホネートを活性成分として含む、医薬組成物。
- 医薬組成物が、医薬的に許容し得る担体または賦形剤をさらに含む、請求項3に記載の医薬組成物。
- 医薬組成物が、血栓症、心筋梗塞、動脈硬化症、炎症、脳卒中、狭心症、血管形成術後の再発性狭窄症および血栓塞栓症からなる群から選択される少なくとも1つの疾患または症状を予防または治療するために使用される、請求項3または4に記載の医薬組成物。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2014/006555 WO2016010178A1 (ko) | 2014-07-18 | 2014-07-18 | 5-클로로-n-({(5s)-2-옥소-3-[4-(5,6-디하이드로-4h-[1,2,4]트리아진-1-일)페닐]-1,3-옥사졸리딘-5-일}메틸)티오펜-2-카르복사미드 메탄설폰산염의 신규 결정형 및 이를 포함하는 약학 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017521500A JP2017521500A (ja) | 2017-08-03 |
JP6450840B2 true JP6450840B2 (ja) | 2019-01-09 |
Family
ID=55078662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017523744A Active JP6450840B2 (ja) | 2014-07-18 | 2014-07-18 | 5−クロロ−n−({(5s)−2−オキソ−3−[4−(5,6−ジヒドロ−4h−[1,2,4]トリアジン−1−イル)フェニル]−1,3−オキサゾリジン−5−イル}メチル)チオフェン−2−カルボキシアミド メタンスルホネートの新規結晶形態および前記結晶形態を含む医薬組成物 |
Country Status (16)
Country | Link |
---|---|
US (1) | US9988372B2 (ja) |
EP (1) | EP3170819B1 (ja) |
JP (1) | JP6450840B2 (ja) |
KR (1) | KR102100357B1 (ja) |
CN (2) | CN106661011B (ja) |
AU (1) | AU2014400894B2 (ja) |
BR (1) | BR112017000351B1 (ja) |
CA (1) | CA2955397C (ja) |
IL (2) | IL297649A (ja) |
MX (1) | MX2017000409A (ja) |
MY (1) | MY190477A (ja) |
PH (1) | PH12017500093A1 (ja) |
RU (1) | RU2663617C1 (ja) |
SG (1) | SG11201700066TA (ja) |
UA (1) | UA116182C2 (ja) |
WO (1) | WO2016010178A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020022186A2 (pt) * | 2018-05-02 | 2021-02-02 | Tianjin Hemay Pharmaceutical Co., Ltd. | formas sólidas de derivados de tiofeno |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100898361B1 (ko) * | 2008-07-03 | 2009-05-20 | 주식회사 레고켐 바이오사이언스 | P4 위치에 사이클릭 아미독심 또는 사이클릭 아미드라존기를 가지는 FXa 저해제, 이의 유도체, 제조방법 및이를 함유하는 의약 조성물 |
KR101037052B1 (ko) | 2009-07-08 | 2011-05-26 | 주식회사 레고켐 바이오사이언스 | 5-클로로-n-(((5s)-2-옥소-3-(4-(5,6-디하이드로-1,2,4-트리아진-1(4h)-일)페닐)-1,3-옥사졸리딘-5-일)메틸)티오펜-2-카르복사미드 유도체의 제조방법 및 그 제조중간체 |
-
2014
- 2014-07-18 US US15/325,521 patent/US9988372B2/en active Active
- 2014-07-18 WO PCT/KR2014/006555 patent/WO2016010178A1/ko active Application Filing
- 2014-07-18 BR BR112017000351-1A patent/BR112017000351B1/pt active IP Right Grant
- 2014-07-18 KR KR1020167035812A patent/KR102100357B1/ko active IP Right Grant
- 2014-07-18 AU AU2014400894A patent/AU2014400894B2/en active Active
- 2014-07-18 IL IL297649A patent/IL297649A/en unknown
- 2014-07-18 UA UAA201701494A patent/UA116182C2/uk unknown
- 2014-07-18 CA CA2955397A patent/CA2955397C/en active Active
- 2014-07-18 CN CN201480080661.8A patent/CN106661011B/zh active Active
- 2014-07-18 JP JP2017523744A patent/JP6450840B2/ja active Active
- 2014-07-18 EP EP14897871.1A patent/EP3170819B1/en active Active
- 2014-07-18 SG SG11201700066TA patent/SG11201700066TA/en unknown
- 2014-07-18 RU RU2017105147A patent/RU2663617C1/ru active
- 2014-07-18 MX MX2017000409A patent/MX2017000409A/es active IP Right Grant
- 2014-07-18 MY MYPI2016704816A patent/MY190477A/en unknown
- 2014-07-18 CN CN201910687566.9A patent/CN110407827B/zh active Active
-
2017
- 2017-01-13 PH PH12017500093A patent/PH12017500093A1/en unknown
- 2017-01-17 IL IL250168A patent/IL250168A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
PH12017500093A1 (en) | 2017-05-22 |
CA2955397C (en) | 2019-01-08 |
UA116182C2 (uk) | 2018-02-12 |
US9988372B2 (en) | 2018-06-05 |
SG11201700066TA (en) | 2017-02-27 |
AU2014400894B2 (en) | 2018-04-19 |
EP3170819A1 (en) | 2017-05-24 |
KR20170023003A (ko) | 2017-03-02 |
CN106661011B (zh) | 2020-01-10 |
RU2663617C1 (ru) | 2018-08-07 |
MX2017000409A (es) | 2017-05-01 |
BR112017000351A2 (pt) | 2017-11-07 |
AU2014400894A1 (en) | 2017-02-02 |
JP2017521500A (ja) | 2017-08-03 |
EP3170819A4 (en) | 2018-05-16 |
MY190477A (en) | 2022-04-22 |
EP3170819B1 (en) | 2019-07-10 |
CN110407827A (zh) | 2019-11-05 |
US20170152251A1 (en) | 2017-06-01 |
IL297649A (en) | 2022-12-01 |
BR112017000351B1 (pt) | 2022-10-25 |
WO2016010178A1 (ko) | 2016-01-21 |
CA2955397A1 (en) | 2016-01-21 |
CN106661011A (zh) | 2017-05-10 |
NZ727829A (en) | 2021-01-29 |
IL250168A0 (en) | 2017-03-30 |
KR102100357B1 (ko) | 2020-04-13 |
CN110407827B (zh) | 2023-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11117875B2 (en) | Crystalline forms, preparation methods and pharmaceutical compositions of ozanimod | |
CN111094290B (zh) | 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途 | |
JP2015525227A (ja) | ダサチニブと、選択された共結晶形成剤とを含んでなる多成分結晶 | |
WO2014076712A2 (en) | Lurasidone hydrochloride solid dispersion | |
KR20010043418A (ko) | 파록세틴 고체 분산액의 제조를 위한 수성화 방법 | |
JP2005533755A (ja) | ランソプラゾール多形及びその調製方法 | |
WO2014127735A1 (zh) | 曲格列汀的固态形式及其制备方法和用途 | |
JP2020500925A (ja) | {[5−(3−クロロフェニル)−3−ヒドロキシピリジン−2−カルボニル]アミノ}酢酸の新規結晶形及びその製造方法 | |
JP6215940B2 (ja) | 8−[(3r)−3−アミノ−1−ピペリジニル]−7−(2−ブチン−1−イル)−3,7−ジヒドロ−3−メチル−1−[(4−メチル−2−キナゾリニル)メチル]−1h−プリン−2,6−ジオンまたはその医薬的に許容され得る塩を含む安定な医薬組成物 | |
WO2016097314A1 (en) | Amorphous and crystalline forms of idelalisib and process for forming the same | |
JP6450840B2 (ja) | 5−クロロ−n−({(5s)−2−オキソ−3−[4−(5,6−ジヒドロ−4h−[1,2,4]トリアジン−1−イル)フェニル]−1,3−オキサゾリジン−5−イル}メチル)チオフェン−2−カルボキシアミド メタンスルホネートの新規結晶形態および前記結晶形態を含む医薬組成物 | |
JP2017524004A (ja) | ビスモデギブの多成分結晶及び選択された共結晶形成剤又は溶媒 | |
RU2730521C2 (ru) | Винорелбина монотартрат и его фармацевтическое применение | |
EA021049B1 (ru) | Способ получения кристаллической формы i ривастигмина гидротартрата | |
WO2008110339A2 (en) | Polymorphs of rivastigmine hydrogentartrate | |
JP2017533911A (ja) | ベラパミル塩酸塩の結晶型 | |
WO2013171766A2 (en) | Saxagliptin solid dispersion | |
JP2015522591A (ja) | 重水素化ω―ジメチル尿素又はその塩の多形物 | |
EP2924024A2 (en) | Solid forms of lorcaserin hydrochloride | |
CN112979639A (zh) | 一种马罗皮坦新晶型及其制备方法 | |
WO2023079093A1 (en) | Polymorphs of the mesylate salt of linaprazan glurate | |
NZ727829B2 (en) | Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition containing same | |
WO2014102832A2 (en) | Saxagliptin hydrochloride solid dispersion | |
WO2014108921A2 (en) | Carvedilol phosphate solid dispersion | |
US20150141457A1 (en) | Elvitegravir solid dispersion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170215 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180118 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180123 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180423 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180515 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180914 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20181009 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181204 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181210 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6450840 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |